Cesana C, Regazzi E, Garau D, Caramatti C, Mangoni L, Rizzoli V
Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano (Milano), Italy.
Haematologica. 1999 Sep;84(9):771-8.
Since limited data concerning quantitative and qualitative differences of CD34+ cells collected after different mobilization schedules are available, we investigated phenotype, proliferative capacity and primitive progenitor cell content of CD34+ cells mobilized with four different regimens.
The number, phenotype, and progenitor cell content of CD34+ cells were investigated in 46 patients mobilized with cyclophosphamide (CY) 7 g/m(2) plus granulocyte colony-stimulating factor (G-CSF, 5 microg/kg) (CY7+G-CSF) (n=16), CY 4 g/m(2) plus G-CSF (CY4+G-CSF) (n=8), IVE [ifosphamide (2.5 g/m(2) for 3 d), etoposide (150 mg/m(2) for 3 d), epirubicin (100 mg/m(2) on day 1)] plus G-CSF (IVE+G-CSF) (n=9), or G-CSF (10 microg/kg) alone (n=13).
The number of CD34+ cells collected per liter of processed blood was significantly higher in the CY7+G-CSF group than in the CY4+G-CSF and G-CSF groups (p </= .005), but not the IVE+G-CSF group. As compared to patients in the CY4+G-CSF group, those mobilized with CY7+G-CSF and IVE+G-CSF produced significantly lower percentages of CD34+ cells lacking CD38, CD33, CD45RA, and HLA-DR (p </= .016, at least). In addition, CY4+G-CSF mobilized CD34+ cells had a significantly higher plating efficiency than the cells mobilized in other ways (p </= r .036). In the G-CSF group, colony-forming cells and long-term culture-initiating cells were significantly lower than in the CY groups (p </= .0014 and </= 013, respectively).
Our data demonstrate that: (i) different mobilization regimens allow the collection of CD34+ cells with distinct phenotypic and proliferative features; (ii) evaluation of the absolute number of CD34+ cells by itself is not a reliable indicator of the clonogenic content of blood mobilized with different chemotherapy regimens; (iii) because of the substantial impact that chemotherapy regimens have on the quantity and quality of collected CD34+ cells, anticancer effects and optimal blood progenitor cell yields should be evaluated for each chemotherapy schedule.
由于关于不同动员方案后采集的CD34+细胞定量和定性差异的可用数据有限，我们研究了用四种不同方案动员的CD34+细胞的表型、增殖能力和原始祖细胞含量。
对46例患者进行了研究，这些患者分别接受以下动员方案：环磷酰胺（CY）7 g/m²加粒细胞集落刺激因子（G-CSF，5 μg/kg）（CY7+G-CSF）（n = 16）、CY 4 g/m²加G-CSF（CY4+G-CSF）（n = 8）、异环磷酰胺（2.5 g/m²，连用3天）、依托泊苷（150 mg/m²，连用3天）、表柔比星（第1天100 mg/m²）加G-CSF（IVE+G-CSF）（n = 9）或单独使用G-CSF（10 μg/kg）（n = 13）。研究了CD34+细胞的数量、表型和祖细胞含量。
CY7+G-CSF组每升处理血液中采集的CD34+细胞数量显著高于CY4+G-CSF组和G-CSF组（p≤0.005），但与IVE+G-CSF组无显著差异。与CY4+G-CSF组患者相比，接受CY7+G-CSF和IVE+G-CSF动员的患者产生的缺乏CD38、CD33、CD45RA和HLA-DR的CD34+细胞百分比显著更低（至少p≤0.016）。此外，CY4+G-CSF动员的CD34+细胞的接种效率显著高于其他方式动员的细胞（p≤0.036）。在G-CSF组中，集落形成细胞和长期培养起始细胞显著低于CY组（分别为p≤0.0014和≤0.013）。
我们的数据表明：（i）不同的动员方案可采集到具有不同表型和增殖特征的CD34+细胞；（ii）仅评估CD34+细胞的绝对数量并非不同化疗方案动员血液中克隆形成细胞含量的可靠指标；（iii）由于化疗方案对采集的CD34+细胞的数量和质量有重大影响，应针对每种化疗方案评估抗癌效果和最佳血液祖细胞产量。
